Author

S. K. Myeni

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 4 Organism:mouse· 3 Research Focus:drug response / drug discovery· 2 Research Focus:benchmarking· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Assay:CITE-seq· 1

Frequent Co-Authors

M. Kikkert· 4 shared D. H. Barouch· 3 shared E. J. Snijder· 3 shared F. Wegmann· 3 shared H. Schuitemaker· 3 shared J. E. M. van der Lubbe· 3 shared R. C. Zahn· 3 shared T. J. Dalebout· 3 shared

Activity by Year

2020-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersImmunology

M. Kikkert

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

A third vaccination with a single T cell epitope protects against SARS-CoV-2 infection in the absence of neutralizing antibodies

I. N. Pardieck, E. T. I. van der Gracht, D. M. B. Veerkamp, F. M. Behr, S. van Duikeren, G. Beyrend, J. Rip, R. Nadafi, T. C. van der Sluis, E. Beyranvand Nejad, N. Mulling, D. J. Brasem, M. G. M. Camps, S. K. Myeni, P. J. Bredenbeek, , R. Arens

A third dose of a single T cell epitope vaccine protects mice from SARS-CoV-2 infection without neutralizing antibodies by enhancing effector-memory and tissue-resident memory T cells.

bioRxiv · Dec 15, 2021 · PreprintImmunology

Ad26.COV2.S-elicited immunity protects against G614 spike variant SARS-CoV-2 infection in Syrian hamsters and does not enhance respiratory disease in challenged animals with breakthrough infection after sub-optimal vaccine dosing

J. E. M. van der Lubbe, S. K. Rosendahl Huber, A. Vijayan, L. Dekking, E. van Huizen, J. Vreugdenhil, Y. Choi, M. R. M. Baert, K. Feddes-de Boer, A. Izquierdo Gil, M. van Heerden, T. J. Dalebout, S. K. Myeni, M. Kikkert, E. J. Snijder, , F. Wegmann

This study shows that a single dose of Ad26.COV2.S vaccine protects Syrian hamsters from G614 SARS-CoV-2 infection and prevents VAERD even with suboptimal immunity.

bioRxiv · Jan 8, 2021 · PreprintImmunology

Immunogenicity and protective efficacy of one- and two-dose regimens of the Ad26.COV2.S COVID-19 vaccine candidate in adult and aged rhesus macaques

L. Solforosi, H. Kuipers, S. K. Rosendahl Huber, J. E. M. van der Lubbe, L. Dekking, D. N. Czapska-Casey, A. Izquierdo Gil, M. Baert, J. Drijver, J. Vaneman, E. van Huizen, Y. Choi, J. Vreugdenhil, S. Kroos, A. H. de Wilde, , R. C. Zahn

This study evaluates one- and two-dose regimens of the Ad26.COV2.S vaccine in rhesus macaques, showing higher antibody responses with two doses and protection against SARS-CoV-2 in aged animals.

bioRxiv · Nov 17, 2020Immunology

Ad26-vector based COVID-19 vaccine encoding a prefusion stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses

R. Bos, L. Rutten, J. E. M. van der Lubbe, M. J. G. Bakkers, G. Hardenberg, F. Wegmann, D. Zuijdgeest, A. H. de Wilde, A. Koornneef, A. Verwilligen, D. van Manen, T. Kwaks, R. Vogels, T. J. Dalebout, S. K. Myeni, , H. Schuitemaker

This paper evaluates a prefusion-stabilized SARS-CoV-2 Spike protein vaccine candidate, Ad26.COV2.S, showing potent neutralizing and Th1-polarized immune responses in mice.

bioRxiv · Jul 30, 2020Immunology